Full Fed. Circ. Limits On-Sale Bar’s Reach In Angiomax Case

Law360, New York (July 11, 2016, 11:37 AM EDT) -- The full Federal Circuit ruled Monday that the on-sale bar invalidating a patent is triggered only by a transaction that “bears the general hallmarks of a sale,” holding that The Medicines Co.’s deal with a supplier for experimental batches of the blood thinner Angiomax did not invalidate its patents.

In a unanimous en banc ruling, the full court reached the opposite conclusion from a panel decision last year that held that The Medicines Co.’s transaction was enough to render its patents on methods of making the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.